Enlivex Therapeutics Ltd. announced that the U.S. Patent and Trademark Office issued a new patent, number US 11,883,429, covering AllocetraTM, the Company?s immunotherapy product candidate. The new patent is expected to provide added intellectual property protection in the United States for the product?s composition and manufacturing method.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.62 USD | 0.00% | +12.50% | -40.00% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.00% | 30.48M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- ENLV Stock
- News Enlivex Therapeutics Ltd.
- Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method